Carregando...
PRDM1 is required for Mantle Cell Lymphoma response to Bortezomib
Mantle cell lymphoma (MCL) is an aggressive form of B cell lymphoma with a poor disease- free survival rate. The proteasome inhibitor, Bortezomib, is approved for treatment of relapsed and refractory MCL and has efficacy in about 30% of patients. However, the precise mechanism of action of Bortezomi...
Na minha lista:
| Principais autores: | , , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2010
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2891394/ https://ncbi.nlm.nih.gov/pubmed/20530581 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1541-7786.MCR-10-0131 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|